Relief Therapeutics Holding AG
RLFTD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $6 | $6 | $3 |
| % Growth | 39.5% | -0.8% | 83.1% | – |
| Cost of Goods Sold | $3 | $2 | $18 | $12 |
| Gross Profit | $6 | $4 | $5 | -$9 |
| % Margin | 69.4% | 68.2% | 79.4% | -258.5% |
| R&D Expenses | $1 | $1 | $12 | $19 |
| G&A Expenses | $9 | $17 | $21 | $16 |
| SG&A Expenses | $10 | $19 | $24 | $16 |
| Sales & Mktg Exp. | $1 | $2 | $3 | $0 |
| Other Operating Expenses | $14 | $94 | $20 | -$1 |
| Operating Expenses | $25 | $115 | $57 | $27 |
| Operating Income | -$19 | -$111 | -$52 | -$34 |
| % Margin | -224.4% | -1,837% | -855.8% | -1,033% |
| Other Income/Exp. Net | -$0 | -$1 | -$2 | -$1 |
| Pre-Tax Income | -$19 | -$112 | -$54 | -$36 |
| Tax Expense | -$2 | -$14 | -$4 | -$1 |
| Net Income | -$17 | -$98 | -$51 | -$35 |
| % Margin | -203.4% | -1,627.4% | -835.2% | -1,045% |
| EPS | -1.36 | -8.35 | -4.8 | -3.86 |
| % Growth | 83.7% | -74% | -24.4% | – |
| EPS Diluted | -1.36 | -8.35 | -4.8 | -3.86 |
| Weighted Avg Shares Out | 13 | 12 | 11 | 9 |
| Weighted Avg Shares Out Dil | 13 | 12 | 11 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $4 | $2 |
| EBITDA | -$17 | -$108 | -$49 | -$33 |
| % Margin | -197% | -1,790.8% | -806.2% | -984.4% |